GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (NAS:ELDN) » Definitions » Shiller PE Ratio

Eledon Pharmaceuticals (Eledon Pharmaceuticals) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eledon Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Eledon Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Shiller PE Ratio Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eledon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eledon Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Eledon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Shiller PE Ratio falls into.



Eledon Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Eledon Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Eledon Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.34/131.7762*131.7762
=-0.340

Current CPI (Mar. 2024) = 131.7762.

Eledon Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -45.654 100.560 -59.826
201409 -48.775 100.428 -64.000
201412 -45.360 99.070 -60.335
201503 -95.579 99.621 -126.429
201506 -64.800 100.684 -84.811
201509 -85.859 100.392 -112.701
201512 -79.379 99.792 -104.820
201603 -82.619 100.470 -108.362
201606 -1.350 101.688 -1.749
201609 -2.610 101.861 -3.377
201612 -1.596 101.863 -2.065
201703 -1.180 102.862 -1.512
201706 -23.760 103.349 -30.295
201709 -7.740 104.136 -9.794
201712 -11.260 104.011 -14.266
201803 -6.480 105.290 -8.110
201806 -6.120 106.317 -7.586
201809 -6.660 106.507 -8.240
201812 -8.820 105.998 -10.965
201903 -9.360 107.251 -11.500
201906 -6.300 108.070 -7.682
201909 -4.010 108.329 -4.878
201912 -5.680 108.420 -6.904
202003 -8.520 108.902 -10.310
202006 -2.740 108.767 -3.320
202009 -5.510 109.815 -6.612
202012 -0.389 109.897 -0.466
202103 -0.570 111.754 -0.672
202106 -0.500 114.631 -0.575
202109 -0.660 115.734 -0.751
202112 -0.600 117.630 -0.672
202203 -0.690 121.301 -0.750
202206 -0.650 125.017 -0.685
202209 -0.730 125.227 -0.768
202212 -4.090 125.222 -4.304
202303 -0.750 127.348 -0.776
202306 -0.400 128.729 -0.409
202309 -0.350 129.860 -0.355
202312 -0.290 129.419 -0.295
202403 -0.340 131.776 -0.340

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eledon Pharmaceuticals  (NAS:ELDN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Eledon Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals (Eledon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.
Executives
Allan Kirk director C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Steven Perrin director, officer: See Remarks C/O ANELIXIS THERAPEUTICS, INC., 1500 DISTRICT AVENUE, BURLINGTON MA 01803
David-alexandre C Gros director, officer: Chief Executive Officer 220 MARLBOROUGH STREET, #6, BOSTON MA 02116
Jan Hillson director C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Paul Sean Little officer: CHIEF FINANCIAL OFFICER SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Bryan E. Smith officer: See Remarks C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
June Lee director C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Israel Biofund Gp Limited Partnership director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Logos Global Management Lp 10 percent owner 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Eledon Pharmaceuticals (Eledon Pharmaceuticals) Headlines

From GuruFocus

Eledon Pharmaceuticals Provides Business and Pipeline Updates

By Stock market mentor Stock market mentor 01-09-2023